| . | Patients with ASS with myocarditis (n = 13) . |
|---|---|
| Age, median [IQR] | 58 [54.25–64.25] |
| Females, n (%) | 6 (46.1) |
| Clinical and biochemical findings | |
| Subclinical onset, n (%) | 7 (53.8) |
| Infarct-like onset, n (%) | 2 (15.4) |
| Arrhythmic onset, n (%) | 2 (15.4) |
| Congestive heart failure onset, n (%) | 2 (15.4) |
| Concomitant myositis, n (%) | 8 (61.5) |
| Increased hs-TnT, n (%) | 12 (92.3) |
| Hs-TnT serum levels, median [IQR] (ng/l) | 88.0 [23.55–311.5] |
| Increased NT-proBNP, n (%) | 11 (84.6) |
| NT-proBNP serum levels, median [IQR] (pg/ml) | 525.5 [243.5–1575.25] |
| Increased CRP, n (%) | 7 (53.8) |
| Increased ESR, n (%) | 7 (53.8) |
| CRP serum levels, median [IQR] (mg/l) | 7.0 [1.7–15.75] |
| ESR serum levels, median [IQR] (mm/1h) | 32.0 [8.0–45.0] |
| Echocardiogaphy | |
| Echocardiogaphic abnormalities, n (%) | 7 (53.8) |
| Reduced LVEF, n (%) | 2 (15.4) |
| LVEF (%), median [IQR] | 58.0 [55.0–60.0] |
| Hypokinesia, n (%) | 3 (23) |
| Diastolic dysfunction, n (%) | 4 (31) |
| 24-h ECG holter analysis | |
| 24-h ECG holter abnormalities, n (%) | 2 (15.4) |
| Frequent VEBs, n (%) | 4 (31) |
| VEBs number, median [IQR] | 1027 [123–1782] |
| CMRI findings | 11 patients |
| Any abnormality, n (%) | 11 (100) |
| LGE areas, n (%) | 10 (91.0) |
| LGE burden (%), median [IQR]a | 2.50 [1.75–3.50] |
| Positive LGE segments (n), median [IQR] | 2 [1-3] |
| Pericardial effusion, n (%) | 9 (81.1) |
| Reduced LVEF, n (%) | 4 (36.4) |
| LVEF (%), median [IQR] | 58.0 [51.25–64.25] |
| EDV-LV (ml), median [IQR] | 123.25 [105.30–141.10] |
| EDV-RV (ml), median [IQR] | 137.40 [105.15–150.10] |
| RVEF (%), median [IQR] | 62.0 [56.5–71.0] |
| Patients with positive T2 ratio on STIR, n (%) | 6 (54.5) |
| Mean T2 ratio, median [IQR] | 1.90 [1.70–1.95] |
| Global native T1 relaxation time (ms), median [IQR] | 1071 [1042.0–1084.0] |
| Increased native T1 mapping (ms) (normal value ≤1045 ms), n (%) | 10 (91.0) |
| ECV (%; global), median [IQR] | 30.5 [27.5–31.0] |
| Increased ECV (normal value ≤27%), n (%) | 11 (100) |
| Increased T2 mapping (normal value ≤50 ms), n (%) | 10 (91.0) |
| Global T2 relaxation time (ms), median [IQR] | 52.7 [51.25–57.20] |
| Global T2 relaxation time in patients with increased T2 relaxation time (ms), median [IQR] | 53.2 [52.0–58.5] |
| Lake Louise criteria | |
| 2009 LLC | |
| Patients with positive regional or global STIR n (%) | 6 (54.5) |
| Patients with positive EGE, n (%) | 0 0 |
| Patients with positive LGE, n (%) | 10 (91.0) |
| 2009 LLC criteria satisfiedb, n (%) | 6 (54.5) |
| 2018 LLC | |
| Patients with positive T1 criteria, n (%) | 10 (91.0) |
| Patients with positive T2 criteria, n (%) | 10 (91.0) |
| 2018 LLC criteria satisfied, n (%)b | 10 (91.0) |
| . | Patients with ASS with myocarditis (n = 13) . |
|---|---|
| Age, median [IQR] | 58 [54.25–64.25] |
| Females, n (%) | 6 (46.1) |
| Clinical and biochemical findings | |
| Subclinical onset, n (%) | 7 (53.8) |
| Infarct-like onset, n (%) | 2 (15.4) |
| Arrhythmic onset, n (%) | 2 (15.4) |
| Congestive heart failure onset, n (%) | 2 (15.4) |
| Concomitant myositis, n (%) | 8 (61.5) |
| Increased hs-TnT, n (%) | 12 (92.3) |
| Hs-TnT serum levels, median [IQR] (ng/l) | 88.0 [23.55–311.5] |
| Increased NT-proBNP, n (%) | 11 (84.6) |
| NT-proBNP serum levels, median [IQR] (pg/ml) | 525.5 [243.5–1575.25] |
| Increased CRP, n (%) | 7 (53.8) |
| Increased ESR, n (%) | 7 (53.8) |
| CRP serum levels, median [IQR] (mg/l) | 7.0 [1.7–15.75] |
| ESR serum levels, median [IQR] (mm/1h) | 32.0 [8.0–45.0] |
| Echocardiogaphy | |
| Echocardiogaphic abnormalities, n (%) | 7 (53.8) |
| Reduced LVEF, n (%) | 2 (15.4) |
| LVEF (%), median [IQR] | 58.0 [55.0–60.0] |
| Hypokinesia, n (%) | 3 (23) |
| Diastolic dysfunction, n (%) | 4 (31) |
| 24-h ECG holter analysis | |
| 24-h ECG holter abnormalities, n (%) | 2 (15.4) |
| Frequent VEBs, n (%) | 4 (31) |
| VEBs number, median [IQR] | 1027 [123–1782] |
| CMRI findings | 11 patients |
| Any abnormality, n (%) | 11 (100) |
| LGE areas, n (%) | 10 (91.0) |
| LGE burden (%), median [IQR]a | 2.50 [1.75–3.50] |
| Positive LGE segments (n), median [IQR] | 2 [1-3] |
| Pericardial effusion, n (%) | 9 (81.1) |
| Reduced LVEF, n (%) | 4 (36.4) |
| LVEF (%), median [IQR] | 58.0 [51.25–64.25] |
| EDV-LV (ml), median [IQR] | 123.25 [105.30–141.10] |
| EDV-RV (ml), median [IQR] | 137.40 [105.15–150.10] |
| RVEF (%), median [IQR] | 62.0 [56.5–71.0] |
| Patients with positive T2 ratio on STIR, n (%) | 6 (54.5) |
| Mean T2 ratio, median [IQR] | 1.90 [1.70–1.95] |
| Global native T1 relaxation time (ms), median [IQR] | 1071 [1042.0–1084.0] |
| Increased native T1 mapping (ms) (normal value ≤1045 ms), n (%) | 10 (91.0) |
| ECV (%; global), median [IQR] | 30.5 [27.5–31.0] |
| Increased ECV (normal value ≤27%), n (%) | 11 (100) |
| Increased T2 mapping (normal value ≤50 ms), n (%) | 10 (91.0) |
| Global T2 relaxation time (ms), median [IQR] | 52.7 [51.25–57.20] |
| Global T2 relaxation time in patients with increased T2 relaxation time (ms), median [IQR] | 53.2 [52.0–58.5] |
| Lake Louise criteria | |
| 2009 LLC | |
| Patients with positive regional or global STIR n (%) | 6 (54.5) |
| Patients with positive EGE, n (%) | 0 0 |
| Patients with positive LGE, n (%) | 10 (91.0) |
| 2009 LLC criteria satisfiedb, n (%) | 6 (54.5) |
| 2018 LLC | |
| Patients with positive T1 criteria, n (%) | 10 (91.0) |
| Patients with positive T2 criteria, n (%) | 10 (91.0) |
| 2018 LLC criteria satisfied, n (%)b | 10 (91.0) |
LGE burden evaluated using the ±3 S.D. method.
LLC suggestive for active myocardial inflammation. n: number; ASS: anti-synthetase syndrome; hs-TnT: high-sensitivity troponin T; LV-EF: left-ventricular ejection fraction; VEBs: ventricular ectopic beats (frequent if higher than 720/24 h); NS-VT: non-sustained ventricular tachycardia; CMRI: cardiac MRI; LV-EDV: left-ventricular end diastolic volume; RV-EDV: right-ventriclular end diastolic volume; BSA: body surface area; ECV: extracellular volume; RV-EF: right-ventricular ejection fraction; STIR: Short-Tau Inversion Recovery; LLC: Lake Louise criteria; EGE: early gadolinium enhancement.
| . | Patients with ASS with myocarditis (n = 13) . |
|---|---|
| Age, median [IQR] | 58 [54.25–64.25] |
| Females, n (%) | 6 (46.1) |
| Clinical and biochemical findings | |
| Subclinical onset, n (%) | 7 (53.8) |
| Infarct-like onset, n (%) | 2 (15.4) |
| Arrhythmic onset, n (%) | 2 (15.4) |
| Congestive heart failure onset, n (%) | 2 (15.4) |
| Concomitant myositis, n (%) | 8 (61.5) |
| Increased hs-TnT, n (%) | 12 (92.3) |
| Hs-TnT serum levels, median [IQR] (ng/l) | 88.0 [23.55–311.5] |
| Increased NT-proBNP, n (%) | 11 (84.6) |
| NT-proBNP serum levels, median [IQR] (pg/ml) | 525.5 [243.5–1575.25] |
| Increased CRP, n (%) | 7 (53.8) |
| Increased ESR, n (%) | 7 (53.8) |
| CRP serum levels, median [IQR] (mg/l) | 7.0 [1.7–15.75] |
| ESR serum levels, median [IQR] (mm/1h) | 32.0 [8.0–45.0] |
| Echocardiogaphy | |
| Echocardiogaphic abnormalities, n (%) | 7 (53.8) |
| Reduced LVEF, n (%) | 2 (15.4) |
| LVEF (%), median [IQR] | 58.0 [55.0–60.0] |
| Hypokinesia, n (%) | 3 (23) |
| Diastolic dysfunction, n (%) | 4 (31) |
| 24-h ECG holter analysis | |
| 24-h ECG holter abnormalities, n (%) | 2 (15.4) |
| Frequent VEBs, n (%) | 4 (31) |
| VEBs number, median [IQR] | 1027 [123–1782] |
| CMRI findings | 11 patients |
| Any abnormality, n (%) | 11 (100) |
| LGE areas, n (%) | 10 (91.0) |
| LGE burden (%), median [IQR]a | 2.50 [1.75–3.50] |
| Positive LGE segments (n), median [IQR] | 2 [1-3] |
| Pericardial effusion, n (%) | 9 (81.1) |
| Reduced LVEF, n (%) | 4 (36.4) |
| LVEF (%), median [IQR] | 58.0 [51.25–64.25] |
| EDV-LV (ml), median [IQR] | 123.25 [105.30–141.10] |
| EDV-RV (ml), median [IQR] | 137.40 [105.15–150.10] |
| RVEF (%), median [IQR] | 62.0 [56.5–71.0] |
| Patients with positive T2 ratio on STIR, n (%) | 6 (54.5) |
| Mean T2 ratio, median [IQR] | 1.90 [1.70–1.95] |
| Global native T1 relaxation time (ms), median [IQR] | 1071 [1042.0–1084.0] |
| Increased native T1 mapping (ms) (normal value ≤1045 ms), n (%) | 10 (91.0) |
| ECV (%; global), median [IQR] | 30.5 [27.5–31.0] |
| Increased ECV (normal value ≤27%), n (%) | 11 (100) |
| Increased T2 mapping (normal value ≤50 ms), n (%) | 10 (91.0) |
| Global T2 relaxation time (ms), median [IQR] | 52.7 [51.25–57.20] |
| Global T2 relaxation time in patients with increased T2 relaxation time (ms), median [IQR] | 53.2 [52.0–58.5] |
| Lake Louise criteria | |
| 2009 LLC | |
| Patients with positive regional or global STIR n (%) | 6 (54.5) |
| Patients with positive EGE, n (%) | 0 0 |
| Patients with positive LGE, n (%) | 10 (91.0) |
| 2009 LLC criteria satisfiedb, n (%) | 6 (54.5) |
| 2018 LLC | |
| Patients with positive T1 criteria, n (%) | 10 (91.0) |
| Patients with positive T2 criteria, n (%) | 10 (91.0) |
| 2018 LLC criteria satisfied, n (%)b | 10 (91.0) |
| . | Patients with ASS with myocarditis (n = 13) . |
|---|---|
| Age, median [IQR] | 58 [54.25–64.25] |
| Females, n (%) | 6 (46.1) |
| Clinical and biochemical findings | |
| Subclinical onset, n (%) | 7 (53.8) |
| Infarct-like onset, n (%) | 2 (15.4) |
| Arrhythmic onset, n (%) | 2 (15.4) |
| Congestive heart failure onset, n (%) | 2 (15.4) |
| Concomitant myositis, n (%) | 8 (61.5) |
| Increased hs-TnT, n (%) | 12 (92.3) |
| Hs-TnT serum levels, median [IQR] (ng/l) | 88.0 [23.55–311.5] |
| Increased NT-proBNP, n (%) | 11 (84.6) |
| NT-proBNP serum levels, median [IQR] (pg/ml) | 525.5 [243.5–1575.25] |
| Increased CRP, n (%) | 7 (53.8) |
| Increased ESR, n (%) | 7 (53.8) |
| CRP serum levels, median [IQR] (mg/l) | 7.0 [1.7–15.75] |
| ESR serum levels, median [IQR] (mm/1h) | 32.0 [8.0–45.0] |
| Echocardiogaphy | |
| Echocardiogaphic abnormalities, n (%) | 7 (53.8) |
| Reduced LVEF, n (%) | 2 (15.4) |
| LVEF (%), median [IQR] | 58.0 [55.0–60.0] |
| Hypokinesia, n (%) | 3 (23) |
| Diastolic dysfunction, n (%) | 4 (31) |
| 24-h ECG holter analysis | |
| 24-h ECG holter abnormalities, n (%) | 2 (15.4) |
| Frequent VEBs, n (%) | 4 (31) |
| VEBs number, median [IQR] | 1027 [123–1782] |
| CMRI findings | 11 patients |
| Any abnormality, n (%) | 11 (100) |
| LGE areas, n (%) | 10 (91.0) |
| LGE burden (%), median [IQR]a | 2.50 [1.75–3.50] |
| Positive LGE segments (n), median [IQR] | 2 [1-3] |
| Pericardial effusion, n (%) | 9 (81.1) |
| Reduced LVEF, n (%) | 4 (36.4) |
| LVEF (%), median [IQR] | 58.0 [51.25–64.25] |
| EDV-LV (ml), median [IQR] | 123.25 [105.30–141.10] |
| EDV-RV (ml), median [IQR] | 137.40 [105.15–150.10] |
| RVEF (%), median [IQR] | 62.0 [56.5–71.0] |
| Patients with positive T2 ratio on STIR, n (%) | 6 (54.5) |
| Mean T2 ratio, median [IQR] | 1.90 [1.70–1.95] |
| Global native T1 relaxation time (ms), median [IQR] | 1071 [1042.0–1084.0] |
| Increased native T1 mapping (ms) (normal value ≤1045 ms), n (%) | 10 (91.0) |
| ECV (%; global), median [IQR] | 30.5 [27.5–31.0] |
| Increased ECV (normal value ≤27%), n (%) | 11 (100) |
| Increased T2 mapping (normal value ≤50 ms), n (%) | 10 (91.0) |
| Global T2 relaxation time (ms), median [IQR] | 52.7 [51.25–57.20] |
| Global T2 relaxation time in patients with increased T2 relaxation time (ms), median [IQR] | 53.2 [52.0–58.5] |
| Lake Louise criteria | |
| 2009 LLC | |
| Patients with positive regional or global STIR n (%) | 6 (54.5) |
| Patients with positive EGE, n (%) | 0 0 |
| Patients with positive LGE, n (%) | 10 (91.0) |
| 2009 LLC criteria satisfiedb, n (%) | 6 (54.5) |
| 2018 LLC | |
| Patients with positive T1 criteria, n (%) | 10 (91.0) |
| Patients with positive T2 criteria, n (%) | 10 (91.0) |
| 2018 LLC criteria satisfied, n (%)b | 10 (91.0) |
LGE burden evaluated using the ±3 S.D. method.
LLC suggestive for active myocardial inflammation. n: number; ASS: anti-synthetase syndrome; hs-TnT: high-sensitivity troponin T; LV-EF: left-ventricular ejection fraction; VEBs: ventricular ectopic beats (frequent if higher than 720/24 h); NS-VT: non-sustained ventricular tachycardia; CMRI: cardiac MRI; LV-EDV: left-ventricular end diastolic volume; RV-EDV: right-ventriclular end diastolic volume; BSA: body surface area; ECV: extracellular volume; RV-EF: right-ventricular ejection fraction; STIR: Short-Tau Inversion Recovery; LLC: Lake Louise criteria; EGE: early gadolinium enhancement.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
